GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shuttle Pharmaceuticals Holdings SHPH · USD

Health Care · US listing · 🇺🇸 United States

Compare

5.19

-7.16%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Shuttle Pharmaceuticals Holdings

From its filings with the US Securities and Exchange Commission

SEC filings

Shuttle Pharmaceuticals Holdings is based in Gaithersburg, Maryland and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SHPH. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $11.7m. At that date it held total assets of $10.5m and shareholders' equity of $2.3m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
31 Aug 2022
Employees
4
Head office
401 PROFESSIONAL DRIVE, GAITHERSBURG, MD, 20879
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. George ScorsisIndependent Chairman of the Board
  • Mr. Christopher CooperInterim Chief Executive Officer
  • Ms. Yuying LiangChief Financial Officer
  • Dr. Tyvin RichChief Medical Officer, Chief Clinical Officer, since 2022$218,000
  • Mr. Adam ChambersDirector
  • Mr. Angel LirianoDirector
  • Mr. Oleh NabytIndependent Director
  • Mr. Robert BlumInvestor Relations

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company has a focused pipeline targeting cancer therapies with radiation therapy.
  • Lead candidate Ropidoxuridine is in development for brain tumors and sarcomas.
  • Company is headquartered in Gaithersburg, Maryland with a clear focus on radiation therapy.

Weaknesses

  • Company has only 4 full-time employees, indicating limited operational capacity.
  • IPO occurred in 2022, suggesting a relatively new company with limited market history.
  • Several product candidates are in pre-clinical stages, indicating early development stages.

Opportunities

  • Expanding applications of radiation therapy could increase market potential for product candidates.
  • Growing focus on cancer treatment may drive demand for novel therapies.
  • Potential for partnerships or collaborations to enhance development capabilities.

Threats

  • Limited employee count may hinder rapid development and market response.
  • Early-stage product candidates face high failure risks in clinical trials.
  • Competition in the biotechnology sector could impact market share.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.